{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:10:02Z","timestamp":1762639802688},"reference-count":4,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T00:00:00Z","timestamp":1232323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The authors assessed whether the use of a topical anti-inflammatory agent at the radiation entry site would prevent radiation-induced skin damage and found that the use of a topical anti-inflammatory agent, such as one containing 10% trolamine salicylate, may reduce skin damage at the radiation entry site if used prophylactically.<\/jats:p>","DOI":"10.1634\/theoncologist.2008-0256","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T17:38:53Z","timestamp":1235756333000},"page":"197-198","source":"Crossref","is-referenced-by-count":5,"title":["Anti-Inflammatory Cream Reduces Skin Damage Induced by Ionizing Radiation"],"prefix":"10.1093","volume":"14","author":[{"given":"Philippe F.","family":"Simard","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M.","family":"Bolton","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy J.","family":"Tarbell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,1,19]]},"reference":[{"key":"2021122207535433000_R1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/0-387-25354-8_3","article-title":"Management of radiation-induced head and neck injury","volume":"128","author":"Blanco","year":"2006","journal-title":"Cancer Treat Res"},{"key":"2021122207535433000_R2","first-page":"801","article-title":"Early and late radiation-induced skin alterations. Part I: Mechanisms of skin changes","volume":"19","author":"Sitton","year":"1992","journal-title":"Oncol Nurs Forum"},{"key":"2021122207535433000_R3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mc.20219","article-title":"Cyclooxygenase-2 as a signaling molecule in radiation-induced bystander effect","volume":"45","author":"Hei","year":"2006","journal-title":"Mol Carcinog"},{"key":"2021122207535433000_R4","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1097\/01.COC.0000074149.95710.40","article-title":"Celecoxib reduces skin damage after radiation: Selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor","volume":"26","author":"Liang","year":"2003","journal-title":"Am J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0256","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/2\/197\/41841441\/oncolo_14_2_197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/2\/197\/41841441\/oncolo_14_2_197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:05:34Z","timestamp":1640160334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/2\/197\/6397489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,19]]},"references-count":4,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,1,19]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0256","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,2,1]]},"published":{"date-parts":[[2009,1,19]]}}}